Polarean Imaging PLC Result of AGM (0623V)

TIDMPOLX

RNS Number : 0623V

Polarean Imaging PLC

18 July 2018

Polarean Imaging Plc

("Polarean" or the "Company")

Result of AGM

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

Enquiries:

 
 Polarean Imaging plc                               www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive Officer                                 Via Walbrook PR 
 Richard Morgan, Chairman 
 
 Northland Capital Partners Limited                                    Tel: [phone] 
                                                                                      6625 
 David Hignell / Gerry Beaney / Jamie Spotswood 
  (Corporate Finance) 
  Vadim Alexandre / Rob Rees (Corporate Broking) 
 
 MC Services (European IR)                                              Tel: [phone] 
                                                                                      2280 
 Raimund Gabriel 
 
 The Life Sciences Division (Financial Adviser) 
 Navid Malik, Director                                                  Mob: [phone] 
 Alia Minhas, CEO                                                       Mob: [phone] 
 
 Walbrook PR                           Tel: [phone] or [e-mail] 
 Anna Dunphy                                                      Mob: [phone] 
  Helen Cresswell                                                      [phone] 
 
 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging (129) Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of (129) Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGSFWFDAFASEEW

(END) Dow Jones Newswires

July 18, 2018 09:28 ET (13:28 GMT)